Baillie Gifford & Co
CLVS

Baillie Gifford & Co’s Clovis Oncology, Inc. CLVS Stock Holding History

Baillie Gifford & Co’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-92
Closed -$1K – 506
2021
Q2 		$1K Hold
92
– – ﹤0.01% 471
2021
Q1 		$1K Sell
92
-50
-35% -$335 ﹤0.01% 445
2020
Q4 		$1K Buy
+142
New +$718 ﹤0.01% 429

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co's CLVS Position: Q3 2021 in Review

Baillie Gifford & Co sold out of Clovis Oncology, Inc. (CLVS) in Q3 2021, closing a stake of 92 shares — an estimated $1K sold.

Baillie Gifford & Co first reported a position in CLVS in Q4 2020 and held it in 3 quarters. The position peaked at $1K in Q2 2021. 157 funds tracked by Wall St. Rank hold CLVS as of Q3 2021.

  • Baillie Gifford & Co reported no remaining Clovis Oncology, Inc. position as of Q3 2021 after selling out during the quarter.
  • Baillie Gifford & Co sold 92 Clovis Oncology, Inc. shares in Q3 2021, an estimated $1K.
  • Baillie Gifford & Co first reported a position in Clovis Oncology, Inc. in Q4 2020 and held it in 3 quarters.
  • Baillie Gifford & Co's Clovis Oncology, Inc. position peaked at $1K in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2021.

Based on Baillie Gifford & Co's 13F filing for Q3 2021, filed 19 Oct 2021.